NBTXR3

搜索文档
Nanobiotix (NasdaqGS:NBTX) Update / Briefing Transcript
2025-09-18 21:02
Nanobiotix (NasdaqGS:NBTX) Update / Briefing September 18, 2025 08:00 AM ET Company ParticipantsJoanne Choi - Head of U.S. Investor RelationsRosy Liao - Senior AssociateLaurent Levy - Co-Founder and CEODavid Dai - DirectorYiwen Zhang - Equity Research AssociateConference Call ParticipantsClémence Thiers - Sell-Side Equity Research AnalystChiara Montironi - Equity Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity AnalystLucy Codrington - Associate Research AnalystOperatorOkay, and ...
Nanobiotix (NasdaqGS:NBTX) Earnings Call Presentation
2025-09-18 20:00
Immunorad September 2025 Data on Phase 1 Trial Safety and preliminary efficacy of NBTXR3/SBRT in combination with Immune Checkpoint Inhibitors in anti-PD-1 resistant patients with melanoma treated in the phase I trial Study 1100 Cohort 3 – Melanoma Subgroup Analysis Jason W. Chan, MD, Ari Rosenberg, MD, Alexander Lam, MD, James Lee, MD, Adil Daud, MD, William A. Stokes, MD,Nabil F. Saba, MD, Frances Collichio, MD, Hyeon Yu, MD, Priya Mody, MD, Jared Weiss, MD, Stergios Moschos, MD,Steven Powell, MD, Shannon ...